SciClone Pharmaceuticals Financials

SciClone Pharmaceuticals Stock Summary

SciClone Pharmaceuticals competes with Biglari Holdings, Rave Restaurant, Cheesecake Factory, Ark Restaurants, and American Clean. SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, offer therapies for oncology, infectious diseases, and cardiovascular disorders in the Peoples Republic of China, the United States, and Hong Kong.

SciClone Pharmaceuticals Key Financial Ratios

Generally speaking, SciClone Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from SciClone Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of SciClone Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that SciClone Pharmaceuticals reports annually and quarterly.

SciClone Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining SciClone Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare SciClone Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SciClone Pharmaceuticals competition to find correlations between indicators driving SciClone Pharmaceuticals's intrinsic value. More Info.SciClone Pharmaceuticals is rated third in return on equity category among related companies. It is currently regarded as top stock in return on asset category among related companies reporting about  0.84  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for SciClone Pharmaceuticals is roughly  1.19 . Comparative valuation analysis is a catch-all model that can be used if you cannot value SciClone Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for SciClone Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SciClone Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.